ストックスクリーナーアプリを入手
8.80
0.23%
0.02
Nuvectis Pharma Inc (NVCT) 最新ニュース
HC Wainwright Forecasts Weaker Earnings for Nuvectis Pharma - MarketBeat
HC Wainwright Comments on Nuvectis Pharma Q1 Earnings - Defense World
HC Wainwright Predicts Nuvectis Pharma Q1 Earnings - MarketBeat
Nuvectis Pharma, Inc. reports 2025 financial results and business highlights - marketscreener.com
Nuvectis Pharma, Inc. SEC 10-K Report - TradingView
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - The Manila Times
Risk Analysis: Does Nuvectis Pharma Inc. have a competitive edgeEarnings Miss & Precise Entry and Exit Recommendations - baoquankhu1.vn
Investment Report: Is Nuvectis Pharma Inc attractive for institutional investorsJuly 2025 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
(NVCT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8%Should You Buy? - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading Up 5.8% – Should You Buy? - Defense World
Is Nuvectis Pharma Inc. stock a buy on dipsQuarterly Growth Report & Real-Time Volume Spike Alerts - bollywoodhelpline.com
Will Nuvectis Pharma Inc. stock outperform value stocksInsider Selling & Precise Trade Entry Recommendations - bollywoodhelpline.com
Investment Report: Will Nuvectis Pharma Inc outperform tech stocksGold Moves & Safe Capital Growth Plans - baoquankhu1.vn
Energy Moves: Is Nuvectis Pharma Inc stock a good pick for beginnersRisk Management & Low Drawdown Trading Techniques - baoquankhu1.vn
Take Profit: Can Nuvectis Pharma Inc maintain its current growth rateBreakout Watch & Smart Allocation Stock Reports - baoquankhu1.vn
Aug Spikes: Can Nuvectis Pharma Inc stock beat analyst upgradesJuly 2025 Recap & Real-Time Volume Spike Alerts - moha.gov.vn
What Wall Street predicts for Nuvectis Pharma Inc. stock price2025 Major Catalysts & Advanced Swing Trade Entry Plans - Улправда
We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st
Will Nuvectis Pharma Inc. stock benefit from commodity pricesSmall Cap Stock Opportunities & Grow Smarter With Pro-Level Research - Улправда
Why (NVCT) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Laidlaw & Co. Initiates Coverage of Nuvectis Pharma (NVCT) with Buy Recommendation - MSN
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5%Here's Why - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Stock Price Up 0.5% – Here’s Why - Defense World
(NVCT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Is Nuvectis Pharma Inc a good long term investmentEx-Dividend Date Alerts & High Return Trading Strategies - earlytimes.in
Why Nuvectis Pharma Inc. stock remains on buy listsFed Meeting & Growth Focused Stock Reports - Улправда
How rising interest rates impact Nuvectis Pharma Inc. stockEarnings Growth Summary & Verified Swing Trading Watchlists - DonanımHaber
Can Nuvectis Pharma Inc. stock beat analyst upgrades2025 Earnings Impact & Daily Growth Stock Investment Tips - DonanımHaber
Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Sentiment Report & Entry and Exit Point Strategies - DonanımHaber
Will Nuvectis Pharma Inc. stock maintain dividend yield2025 Risk Factors & Weekly Stock Breakout Alerts - DonanımHaber
Weekly Recap: Will Nuvectis Pharma Inc. stock keep outperforming rivalsMarket Trend Summary & Capital Efficient Trade Techniques - bolumsonucanavari.com
Nuvectis Pharma announces initiation of Phase 1b study of NXP900 - MSN
Nuvectis Begins Phase 1b Study to Address Drug Resistance in Lung Cancer - socialunderground.co
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib By Investing.com - Investing.com Nigeria
Positive Recommendation on Nuvectis Pharma Driven by Promising Lead Candidate and Milestone Clinical Studies - TipRanks
Nuvectis Pharma Starts Phase 1b Study With Osimertinib for Non-Small Cell Lung Cancer - marketscreener.com
Nuvectis initiates phase 1b trial combining NXP900 with osimertinib - Investing.com
Nuvectis Pharma announces the initiation of the phase 1b study of NXP900 in combination with osimertinib in patients with NSCLC - marketscreener.com
Nuvectis Pharma Initiates Phase 1b Study of NXP900 in Combination with Osimertinib for EGFRmut+ NSCLC Patients - Quiver Quantitative
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC - Sahm
Precision Trading with Nuvectis Pharma Inc. (NVCT) Risk Zones - Stock Traders Daily
Nuvectis Pharma Shares Gain Momentum on Analyst Backing and Clinical Progress - AD HOC NEWS
Nuvectis Pharma (NVCT) Stock Analysis Report | Financials & Insights - Benzinga
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; retail investors who hold 44% profited and so did insiders - Yahoo Finance
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) market cap rose US$18m last week; individual investors who hold 44% profited and so did insiders - simplywall.st
Technical Reactions to NVCT Trends in Macro Strategies - news.stocktradersdaily.com
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% HigherHere's What Happened - MarketBeat
Nuvectis Pharma (NASDAQ:NVCT) Trading 9.8% Higher – Here’s What Happened - Defense World
Nuvectis Pharma stock rating reiterated at Buy by H.C. Wainwright - Investing.com Australia
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):